



FOR IMMEDIATE RELEASE

Invivotek Awarded Full AAALAC Accreditation for Excellence in Animal Care and Use

Hamilton, NJ. July 14, 2014 - Invivotek L.L.C., a member of the Genesis Biotechnology Group, LLC is pleased to announce that its animal research facility was awarded full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). AAALAC promotes the humane treatment of animals in science worldwide through voluntary accreditation and assessment programs. AAALAC recognizes the highest standards for animal care and use in 38 countries.

Invivotek was established in 2012. In 2013, Invivotek received the Innovation and Achievement Award from Allentown, Inc. for its excellence in animal facility design, planning, construction and operations. As an AAALAC accredited facility, Invivotek provides further assurance to Invivotek's pharmaceutical and biotechnology clients of its commitment to setting, achieving and maintaining the highest standards for animal welfare in science.

In announcing the award of full accreditation, AAALAC's Council on Accreditation specifically commended Invivotek for its "excellent program of laboratory animal care and use." The Council also commented on Invivotek's impeccably clean and well maintained facilities, its design, high quality architectural finishes and excellent equipment and Invivotek's strong commitment to the highest accreditation standards. The Council also recognized "the knowledge, experience and dedication of the Facility Manager."

Invivotek is located in "Einstein's Alley", the research and technology corridor in Hamilton, New Jersey, which is easily accessible to biotech and pharmaceutical companies and academic biomedical centers in New York, New Jersey, and Pennsylvania. Invivotek offers both custom and standard pre-clinical services to support drug discovery and development programs for its clients. The company portfolio includes bioassays designed to support in vivo testing of compounds related to immunology and inflammation, cancer, diabetes, cardiovascular, obesity, neurodegenerative disorders and other diseases and conditions. Invivotek's in vivo testing capabilities are supported by biochemical and molecular biology techniques, as well as functional assays using primary cell cultures established from various animal tissues under disease model and normal conditions. These assays provide tools to study mechanisms of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers.

Invivotek™ is a member of the Genesis Biotechnology Group® (GBG), a consortium of vertically integrated entities pursuing clinical diagnostic testing, preclinical and translational research, and the manufacturing and distribution of life science products. GBG's combined research scientific community creates and sustains drug development and diagnostic programs for targeting infectious, metabolic, inflammatory, and autoimmune diseases, as well as cancer and other issues relating to women's health.

To find out more, please visit www.invivotek.com

Contact:

Dr. Olesia Buiakova

Chief Scientific Officer

Ph: (609) 249-9565

obuiakova@invivotek.com

###